SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 203.18-1.4%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cheryl Galt who wrote (29589)12/13/1999 3:20:00 PM
From: Mudcat  Read Replies (2) of 32384
 
Interesting comment in the Rueters News release:

"After hearing the FDA's evaluation, the panel recommended that Ligand conduct a new study of Targretin compared to another CTCL treatment. Dr. Richard Simon, chief of the National Cancer Institute's biometric research branch, said such a study, which could be done after the drug hits the market, was needed 'to see whether we really have symptomatic improvement here.'

So panel gave approval but Ligand has to do a study to see if targretin really works?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News